SAREUM HOLDINGS PLC

Director's Dealing • Dec 29, 2022

National Storage Mechanism | Additional information

RNS Number : 2434L

Sareum Holdings PLC

29 December 2022

Sareum Holdings PLC

("Sareum" or the "Company")

Director's Dealing

Cambridge, UK, 29 December - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, announces that Dr Stephen Parker, Non-Executive Chairman, purchased 19,972 ordinary shares of 0.0125 pence each in the Company ("Ordinary Shares") at an average price of 77.6 pence per share on 28 December 2022.  Shares are held in either Dr. Parker's SIPP or an ISA account.

The notification below, which has been made in accordance with the requirements of the Market Abuse Regulation, provides further details.

Following the transaction, Dr Parker has a holding in Sareum of 103,660 Ordinary Shares, from a previous holding of 83,688 Ordinary Shares.

PDMR Notification Form:

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Stephen Parker
2	Reason for the notification
a)	Position/status	Non-Executive Chairman
b)	Initial notification/amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Sareum Holdings plc
b)	LEI	213800PKERN2DY8FFM72
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument		Ordinary shares of 0.0125 pence each in the share capital of Sareum Holdings plc
	Identification code		GB00B02RFS12
b)	Nature of the transaction		Purchase of shares
c)	Price(s) and volume(s)
				Price(s)	Volume(s)
	Hargreaves Lansdown SIPP			£0.78	12,820
	Barclays Investment ISA			£0.769	7,152
d)	Aggregated information
	-      Aggregated volume		19,972 ordinary shares
	-      Weighted Average Price		77.61 pence per share
e)	Date of the transaction		28 December 2022
f)	Place of the transaction		London Stock Exchange (AIM)

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014, which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.

- Ends -

For further information, please contact: 

Sareum Holdings plc Tim Mitchell, CEO	01223 497700
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman	020 7409 3494
Peel Hunt LLP (Joint Corporate Broker) James Steel	020 7418 8900
Hybridan LLP (Joint Corporate Broker) Claire Noyce	020 3764 2341
Consilium Strategic Communications (Financial PR) Jessica Hodgson / Davide Salvi / Stella Lempidaki	0203 709 5700

About Sareum

Sareum Holdings (AIM:SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC 1801, simultaneously inhibits TYK2 and JAK1. SDC1801 is a potential treatment for a range of autoimmune diseases. Sareum is also developing SDC1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHEKLFLLLLFFBX